摘要
肺癌是导致男性癌症死亡的主要原因,也是全世界女性癌症死亡的第二大原因。大多数新确诊的肺癌患者因已经发生转移而无法手术治疗。尽管目前放化疗和靶向治疗改善了临床疗效,但总体的存活率仍然很低。免疫检查点的封锁,特别是对程序性死亡-1(PD-1)受体及其配体PD-L1的封锁,在晚期或转移性肺癌患者的临床前和临床研究中取得了很大进展,提高了患者生存率。然而,仍有大量患者对阻断治疗没有显示出较好的临床疗效,本文总结了几种可能的有效性预测因素以指导肺癌的PD-1/PD-L1阻断治疗。
Lung cancer is the leading cause of cancer deaths in males and the second leading cause of deaths in females worldwide.Most newly diagnosed lung cancer patients cannot undergo surgery because the disease has already metastasized.Although chemoradiotherapy and targeted therapy have improved clinical outcomes,overall survival remains poor.Immune checkpoint blockade,especially blockade of programmed death-1(PD-1)receptor and its ligand PD-L1,has achieved great progress and improved survival in patients with advanced or metastatic lung cancer in preclinical and clinical studies.However,a large number of patients have not responded to the blockade treatment.Several possible predictive factors were summarized in this paper to guide the treatment of lung cancer with PD1/PD-L1 blockade.
作者
吴笑驰
倪磊
WU Xiao-chi;NI Lei(Department of Respiratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Respiratory Medicine,People's Hospital of Pudong New District, Shanghai 201201,China)
出处
《实用药物与临床》
CAS
2019年第9期980-984,共5页
Practical Pharmacy and Clinical Remedies
关键词
程序性死亡-1受体及其配体
肺癌
预测因素
Programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1)
Lung cancer
Predictive factors
